I asked what you thought was the best stock investment choice on Cashapp's investing platform and you answered HIMS. Do you still think HIMS is best?

I apologize for any confusion caused. Based on the information I have, I can now provide the final answer. 1. **Intrinsic Value and Market Price**: HIMS's market price of $23.08 is significantly higher than its intrinsic value, which was calculated to be approximately $6.795 using the DCF and Relative valuation methods. This indicates that the stock may be overvalued. 2. **Short Interest and Market Performance**: Despite the high intrinsic value, short interest in HIMS has grown significantly, and the stock has outperformed the S&P 500. However, this strong market performance may not be indicative of future growth. 3. **Financial Ratios**: The company's P/E ratio is negative at -2131.09, which suggests that the company is not profitable or that the market has high expectations for future earnings. The P/B ratio of 13.84 and P/S ratio of 4.22 also indicate that the stock may be overvalued compared to its sales and book value. 4. **Recent News**: While BofA Securities increased the price target to $25, Travis Hoium, a Motley Fool analyst, has positions in HIMS and is cautious about the impact of GLP-1 semaglutide on the company's business. The uncertainty surrounding the longevity of the compounded GLP-1 opportunity should be closely observed. Given these points, while HIMS has shown strong performance and growth potential, it may not be the best investment choice at this time given its high market price relative to its intrinsic value and the potential risks associated with the GLP-1 semaglutide situation. Investors should carefully consider these factors and their investment goals before making a decision.